Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated (mut) advanced breast cancer (ABC): Baseline biomarker analysis and progression-free survival (PFS) by duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy in the BYLieve study Meeting Abstract


Authors: Dejan, J.; Rugo, H. S.; Chia, S. K. L.; Lerebours, F.; Ruiz-Borrego, M.; Drullinsky, P.; Ciruelos, E. M.; Neven, P.; Park, Y. H.; Arce, C. H.; Gu, E.; Joshi, M.; Roux, E.; Akdere, M.; Turner, N. C.
Abstract Title: Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated (mut) advanced breast cancer (ABC): Baseline biomarker analysis and progression-free survival (PFS) by duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy in the BYLieve study
Meeting Title: 2022 ASCO Annual Meeting
Journal Title: Journal of Clinical Oncology
Volume: 40
Issue: 16 Suppl.
Meeting Dates: 2022 Jun 3-7
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2022-06-01
Language: English
ACCESSION: WOS:000863680300075
PROVIDER: wos
DOI: 10.1200/JCO.2022.40.16_suppl.1018
Notes: Meeting Abstract: 1018 -- This meeting was also held virtually -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors